We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Flagellin-PAc Fusion Protein is a High-efficacy Anti-caries Mucosal Vaccine.
- Authors
Sun, Y.; Shi, W.; Yang, J.Y.; Zhou, D.H.; Chen, Y.Q.; Zhang, Y.; Yang, Y.; He, B.X.; Zhong, M.H.; Li, Y.M.; Cao, Y.; Xiao, Y.; Li, W.; Yu, J.; Li, Y.H.; Fan, M.W.; Yan, H.M.
- Abstract
We previously demonstrated that an anti-caries DNA vaccine intranasally administered with recombinant flagellin protein as a mucosal adjuvant enhanced salivary IgA response and conferred better protection against caries. However, the relatively weak immunogenicity of DNA vaccines and the necessity for a large quantity of antigens remain significant challenges. Here, we fused the flagellin derived from E. coli (KF) and target antigen PAc containing the A-P fragment of PAc from S. mutans (rPAc) to produce a single recombinant protein (KF-rPAc). The abilities of KF-rPAc to induce rPAc-specific mucosal and systemic responses and protective efficiency against caries following intranasal immunization were compared with those of rPAc alone or a mixture of rPAc and KF (KF + rPAc) in rats. Results showed that KF-rPAc promoted significantly higher rPAc-specific antibodies in serum as well as in saliva than did an equivalent dose of rPAc alone or a mixture of KF + rPAc. Intranasal immunization of 8.5 µg KF-rPAc could achieve 64.2% reduction of dental caries in rats. In conclusion, our study demonstrated that flagellin and PAc fusion strategy is promising for anti-caries vaccine development, and KF-rPAc could be used as an anti-caries mucosal vaccine.
- Subjects
FLAGELLIN; MUCOUS membranes; DENTAL caries vaccines; IMMUNOGLOBULIN A; ANTIGENS; DNA vaccines; ESCHERICHIA coli; RECOMBINANT proteins; INTRANASAL medication; IMMUNIZATION; LABORATORY rats
- Publication
Journal of Dental Research, 2012, Vol 91, Issue 10, p941
- ISSN
0022-0345
- Publication type
Article
- DOI
10.1177/0022034512457684